

Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections)

<https://marketpublishers.com/r/N868C661E28EN.html>

Date: January 2009

Pages: 180

Price: US\$ 3,500.00 (Single User License)

ID: N868C661E28EN

Abstracts

A nosocomial, or hospital-acquired, infection is a new infection that is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, This type of infection is also known as a hospital-acquired infection (or more generically healthcare-associated infections).

Marketing planners in the pharmaceutical or diagnostic industries should have an understanding of the market impact of nosocomial infections, as it will be an important consideration in these markets into the near future.

This report. Hospital Acquired Infections (Nosocomial) : Diagnostic and Pharmaceutical Market Considerations : MRSA, HAP, Cdiff and Other market impact of treating the following infections are discussed in detail:

Acinetobacter baumannii

Clostridium difficile

Gastroenteritis

Hospital-acquired pneumonia (HAP) and ventilator associated pneumonia

Methicillin resistant staphylococcus aureus MRSA

Pseudomonas aeruginosa

Staphylococcus aureus

Stenotrophomonas maltophilia

Tuberculosis

Urinary tract infection

Vancomycin-resistant enterococcus

This report covers nosocomial infection diagnosis and therapeutics in a broad sense. It does not go into the detail of the dynamics of individual products in the marketplace. It discusses, however, the status of the field of nosocomial infection diagnostics and therapeutics, as a setting-specific field of application.

The Most Recent and Relevant Epidemiological Statistics on HAIs

There is no 'nosocomial infection' market per se, it is reflected in sales and revenues of all infectious disease testing and therapeutics. Therefore Kalorama's market analysis in this report considers primarily the epidemiological considerations and the sizes patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital environment in order to try and construct a picture of the nosocomial testing needs.

Estimates of Market Impact

As mentioned above, the primary focus of this report is on the bacterial form of nosocomial infections, and those with significant impact on the hospital setting and markets. In looking at these infections, we consider the diagnostic and therapeutics technologies that are currently available and attempt to project trends in these product areas.

Company Profiles and Competitive Assessment

This report examines the key players in HAI infection diagnostics and pharmaceutical treatment, their revenues, and activity in the market. To some extent, we are limited by the activity of the industries associated with the diagnosis and treatment of these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology. This presages opportunities for new competitors

The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, research scientists, business development managers and marketing managers.

Contents

CHAPTER ONE: EXECUTIVE SUMMARY

Specific Nosocomial Infections

Acinetobacter Baumannii

Clostridium Difficile

Gastroenteritis

Hospital-Acquired Pneumonia (HAP)

Ventilator-Associated Pneumonia (VAP)

Pseudomonas Aeruginos

Staphylococcus Aureus/Methicillin-Resistant Staphylococcus Aureus

Stenotrophomonas Maltophilia

Tuberculosis

Urinary Tract Infections

Vancomycin-Resistant Enterococcus

Scope and Methodolog

Market Considerations

Trends Affecting Nosocomial Infection Applications

CHAPTER TWO: OVERVIEW OF NOSOCOMIAL INFECTIONS

Overview

Specific Nosocomial Infections

Acinetobacter Baumannii

Clostridium Difficile

Gastroenteritis

Hospital-Acquired Pneumonia

Healthcare-Associated Pneumonia

Hospital-Acquired Pneumonia

Ventilator-Associated Pneumonia

Pseudomonas Aeruginosa

Staphylococcus Aureus

Stenotrophomonas maltophilia

Tuberculosis

Urinary Tract Infections

CHAPTER THREE: DRUG-RESISTANT NOSOCOMIAL INFECTIONS

Overview

Drug-Resistant Acinetobacter

Drug-Resistant C. Difficile

Drug-Resistant Enterococci

Drug-Resistant Pneumonia

Drug-Resistant Pseudomonas Aeruginosa

Drug-Resistant Staphylococcus Aureus

Drug-Resistant Tuberculosis

Drug-Resistance/Susceptibility Testing

Genotypic Methods

DNA Sequencing

Solid-phase Hybridization Techniques

Microarrays

Real-time Polymerase Chain Reaction Techniques

Phenotypic Method

Phage-based Assay

Colorimetric Method

The Nitrate Reductase Assay

CHAPTER FOUR: EPIDEMIOLOGICAL MARKET CONSIDERATIONS

Overview

Acinetobacter Baumannii

Clostridium Difficile

Enterococci

Drug-Resistant Pneumonia

Pseudomonas aeruginosa

Staphylococcus aureus

Drug Resistant Tuberculosis

CHAPTER FIVE: COMPANY SNAPSHOTS

Abbott Pharmaceuticals (Division of Abbott Laboratories)

AdvanDx, Inc.

Becton Dickinson and Company

Binax, Inc. (Division of Inverness Medical Innovations)

Cellestis

Cepheid

GeneOhm Sciences (Division of Becton Dickinson)

GlaxoSmithKline plc

Meridian Bioscience, Inc.

Merck & Co.

Schering-Plough

Techlab, Inc.

Trek Diagnostics Systems, Ltd. (A Subsidiary of Magellan Biosciences)

Volu Sol

CHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS

First Conclusion

Implications

Second Conclusion

Implications

Third Conclusion

Implications

Fourth Conclusion

Implications

Fifth Conclusion

Implications

Sixth Conclusion

Implications

Seventh Conclusion

Implications

I would like to order

Product name: Nosocomial Infections: Market Impact on Diagnostics and Therapeutics: (MRSA, HAP, C. diff and other Hospital Acquired Infections)

Product link: <https://marketpublishers.com/r/N868C661E28EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N868C661E28EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

